Compare · ORKA vs TKNO
ORKA vs TKNO
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and Alpha Teknova Inc. (TKNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and TKNO operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $6.74B, about 16.8x TKNO ($400.5M).
- ORKA has been more active in the news (11 items in the past 4 weeks vs 6 for TKNO).
- ORKA has more recent analyst coverage (11 ratings vs 9 for TKNO).
- Company
- Oruka Therapeutics Inc.
- Alpha Teknova Inc.
- Price
- -
- -
- Market cap
- $6.74B
- $400.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 11
- 6
- Recent ratings
- 11
- 9
Latest ORKA
- Chief Commercial Officer Edwards Larry Todd was granted 100,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Edwards Larry Todd
- Oruka Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
- SEC Form S-3 filed by Oruka Therapeutics Inc.
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $782,882 worth of shares (7,000 units at $111.84) as part of a pre-agreed trading plan (SEC Form 4)
- General Counsel Quinlan Paul T exercised 52,000 shares at a strike of $11.60 and sold $5,641,409 worth of shares (52,000 units at $108.49) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 10,000 shares at a strike of $15.69 and sold $1,066,572 worth of shares (10,000 units at $106.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by Oruka Therapeutics Inc.
- Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Latest TKNO
- Alpha Teknova upgraded by BTIG Research with a new price target
- SEC Form 10-Q filed by Alpha Teknova Inc.
- Alpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Teknova Reports Second Quarter 2026 Financial Results
- Teknova Launches Build-Tek™, a Proprietary AI Reagent Assistant That Allows Customers to Configure Complex Custom Product Requests in Minutes
- Roth Capital initiated coverage on Alpha Teknova with a new price target
- Teknova to Report Second Quarter 2026 Financial Results on August 5, 2026
- Director Demski Martha J disposed of 12,000 shares and acquired 12,000 shares, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Vos Alexander
- SEC Form 4 filed by Director Robertson Brett